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Introduction {#art41017-sec-0005}
============

The therapeutic methods available to treat antineutrophil cytoplasmic antibody (ANCA)--associated vasculitides (AAVs) expanded with the approval of rituximab (RTX) as an alternative therapy to cyclophosphamide (CYC) as the induction treatment for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) [1](#art41017-bib-0001){ref-type="ref"}, [2](#art41017-bib-0002){ref-type="ref"}. As treatment approaches and patient survival have improved over the past decades, longer‐term outcome and complications attributable to either the disease or immunosuppressive therapy have moved into the research focus. Consequently, recent reports have highlighted an increased frequency of venous thromboembolism (VTE) events in patients with AAV. Analysis of a randomized controlled trial that included patients with GPA enrolled in the Wegener\'s Granulomatosis Etanercept Trial (WGET) demonstrated an incidence of VTE of 7.0 per 100 person‐years [3](#art41017-bib-0003){ref-type="ref"}. An increased likelihood of VTE was reported in a population‐based incident AAV cohort, which was driven by a significantly increased risk of developing deep venous thrombosis (DVT) [4](#art41017-bib-0004){ref-type="ref"}. Analysis of a large cohort of patients with eosinophilic granulomatosis with polyangiitis (EGPA), GPA, and MPA demonstrated occurrence of VTE in 8.2%, 8.0%, and 7.8% of patients, respectively [5](#art41017-bib-0005){ref-type="ref"}. More recently, analysis of data derived from several trials conducted by the European Vasculitis Society showed the occurrence of VTE in 41 (9.8%) of 417 patients with GPA or MPA [6](#art41017-bib-0006){ref-type="ref"}. While VTE is now acknowledged as a commonly occurring complication of AAV, its pathogenesis remains ill‐defined. Several factors have been considered to play a role in VTE pathogenesis, including the presence of antiplasminogen antibodies [7](#art41017-bib-0007){ref-type="ref"} and excess thrombin generation facilitated by tissue factor, microparticles, and neutrophil extracellular traps [8](#art41017-bib-0008){ref-type="ref"}.

The aim of the current study was to further explore the relationship between VTE and AAV through analysis of data from the Rituximab in ANCA‐Associated Vasculitis (RAVE) trial [1](#art41017-bib-0001){ref-type="ref"}. This trial allowed for prospective follow‐up of patients with GPA and MPA and presented the first opportunity to study the impact of 2 different induction treatment strategies, namely RTX and CYC, on the occurrence of VTE events.

Patients and Methods {#art41017-sec-0006}
====================

 {#art41017-sec-0007}

### Study design and treatment regimens {#art41017-sec-0008}

The RAVE study was a double‐blind, placebo‐controlled trial in which 197 patients were randomized to receive either RTX (375 mg/m^2^ weekly for 4 weeks; n = 99) or CYC (2 mg/kg body weight for 3--6 months) followed by maintenance treatment with azathioprine (2 mg/kg body weight, maximum dosage 150 mg/day; n = 98). Glucocorticoids were tapered and withdrawn within 5.5 months in both groups. Detailed trial design and the respective results for short‐ and the long‐term follow‐up have been previously described [1](#art41017-bib-0001){ref-type="ref"}, [9](#art41017-bib-0009){ref-type="ref"}.

### Definitions of outcome variables {#art41017-sec-0009}

Patients were classified according to their AAV diagnosis (GPA or MPA) based on the 1994 Chapel Hill Consensus Conference Nomenclature for Vasculitis [10](#art41017-bib-0010){ref-type="ref"}. Patients were further classified according to either proteinase 3 (PR3)--ANCA or myeloperoxidase (MPO)--ANCA. Information related to patient demographic characteristics, newly diagnosed/relapsing disease, specific organ involvement, treatment, and outcome was collected. Vasculitis activity was assessed using the Birmingham Vasculitis Activity Score for Wegener\'s Granulomatosis (BVAS/WG) [11](#art41017-bib-0011){ref-type="ref"}, and the Vasculitis Damage Index was used to grade the respective damage [12](#art41017-bib-0012){ref-type="ref"}. The occurrence of either DVT, pulmonary embolism (PE), or both was considered a VTE event.

### Statistical analysis {#art41017-sec-0010}

For baseline characteristics, the number and percent of patients, mean ± SD, or median with interquartile range was used for analysis, as appropriate. Characteristics between patients with and those without VTE were compared by Student\'s *t*‐test or Mann‐Whitney test for continuous data and chi‐square test or Fisher\'s exact test for categorical data. Spearman\'s correlation coefficient was used to report the relationship between VTE and named factors or states.

Kaplan‐Meier curves were plotted for the occurrence of first VTE events and significant variables. Survival curves were compared by log rank test. Univariate Cox regression models were used to assess the effect of factors and states in patients with and those without VTE. For every significant parameter in univariate analyses, a multivariate Cox regression model with adjustment for age and sex was applied. Findings of the univariate and multivariate analyses were assessed using hazard ratios (HRs) and 95% confidence intervals (95% CIs). *P* values less than 0.05 were considered significant.

Results {#art41017-sec-0011}
=======

 {#art41017-sec-0012}

### Patient characteristics stratified by VTE {#art41017-sec-0013}

Of the 197 patients enrolled in the RAVE trial, 42 (21.3%) received anticoagulation therapy as either thromboprophylaxis or due to an earlier medical history necessitating anticoagulation treatment (such as atrial fibrillation). VTE events were recorded in 16 patients. Of these, 11 patients had DVT, 4 had PE, and 1 had concomitant DVT and PE. Overall, the average time from baseline to VTE was 1.5 months (range 1.0--2.75) (see Supplementary Table [1](#art41017-sup-0001){ref-type="supplementary-material"}, available on the *Arthritis & Rheumatology* web site at <http://onlinelibrary.wiley.com/doi/10.1002/art.41017/abstract>).

A higher BVAS/WG at baseline was recorded for patients with VTE versus those without VTE (HR 10 \[95% CI 9--11.75\] versus 8 \[95% CI 6--10\]; *P* = 0.017). We observed a higher frequency of VTE events among patients with PR3‐ANCA (15 events among 133 patients) than among those with MPO‐ANCA (1 event among 64 patients) (*P* = 0.016). Moreover, pulmonary hemorrhage and heart involvement were more frequent in the VTE group (*P* = 0.004 and *P* = 0.001, respectively). Of the 16 VTE events, 7 occurred in RTX‐treated patients and 9 in CYC‐treated patients (*P* = 0.558). In contrast, sinusitis was less frequently observed in patients who experienced a VTE event than those who did not (31.3% versus 56.9%; *P* = 0.048) (see Supplementary Table [2](#art41017-sup-0002){ref-type="supplementary-material"}, <http://onlinelibrary.wiley.com/doi/10.1002/art.41017/abstract>). A positive correlation was observed between VTE and heart involvement (r = 0.24, *P* \< 0.01), pulmonary hemorrhage (r = 0.21, *P* \< 0.01), positive PR3‐ANCA (r = 0.17, *P* \< 0.05), BVAS/WG (r = 0.17, *P* \< 0.05), and the presence of red blood cell (RBC) casts (r = 0.373, *P* \< 0.001). There was a negative association between VTE and eye involvement (r = --0.16, *P* \< 0.05) and sinusitis (r = --0.14, *P* \< 0.05) (see Supplementary Table [3](#art41017-sup-0003){ref-type="supplementary-material"}, available on the *Arthritis & Rheumatology* web site at <http://onlinelibrary.wiley.com/doi/10.1002/art.41017/abstract>). Kaplan‐Meier curves for pulmonary hemorrhage, positive PR3‐ANCA, and RBCs are shown in Figure [1](#art41017-fig-0001){ref-type="fig"}.

![Kaplan‐Meier analysis of the association between venous thromboembolism (VTE) and pulmonary hemorrhage, proteinase 3 (PR3) positivity, and the presence of red blood cell (RBC) casts. **A**, Event‐free survival of patients with and patients without pulmonary hemorrhage (P \< 0.003). **B**, Time to VTE event according to the specific antigen (PR3 versus myeloperoxidase \[MPO\]) (*P* \< 0.018). **C**, Time to VTE event in patients with RBC casts compared to those without significant RBC casts (*P* \< 0.001). All analyses were calculated from trial entry.](ART-71-1888-g001){#art41017-fig-0001}

### Predictors of VTE {#art41017-sec-0014}

Univariate analyses were performed to identify variables associated with VTE. Among clinical factors found to have significant values, we demonstrated heart involvement (HR 17.408 \[95% CI 2.247--134.842\]; *P* = 0.006), PR3 positivity (HR 7.731 \[95% CI 1.021--58.545\]; *P* = 0.048), pulmonary hemorrhage (HR 3.889 \[95% CI 1.448--10.448\]; *P* = 0.008), and presence of RBCs (HR 15.617 \[95% 3.491--69.854\]; *P* \< 0.001) to be positively associated with VTE events. The frequency of VTE was similar in both treatment groups (RTX versus CYC) (HR 0.747 \[95% 0.278--2.006\]; *P* = 0.563), and there was no difference between newly diagnosed patients and patients with relapsing disease (HR 1.067 \[95% CI 0.400--2.844\]; *P* = 0.896) (Table [1](#art41017-tbl-0001){ref-type="table"}). Multivariate models adjusted for age and sex were used to confirm the associations identified by univariate analyses. After adjustment for demographic variables, the associations between VTE and the presence of heart involvement (HR 21.836 \[95% CI 2.566--185.805\]; *P* = 0.005), pulmonary hemorrhage (HR 3.91 \[95% CI 1.453--10.522\]; *P* = 0.007), PR3 positivity (HR 9.12 \[95% CI 1.158--71.839\]; *P* = 0.036), and presence of RBCs (HR 16.455 \[95% CI 3.607--75.075\]; *P* \< 0.001) remained significant (Table [2](#art41017-tbl-0002){ref-type="table"}).

###### 

Univariate Cox regression results indicating the association between clinical variables and VTE events in 197 patients with antineutrophil cytoplasmic antibody--associated vasculitis[\*](#art41017-note-0006){ref-type="fn"}

  Variable                                                    Median value or % of patients                 HR (95% CI)               *P*
  ----------------------------------------------------------- --------------------------------------------- ------------------------- ---------
  Demographics and baseline clinical characteristics                                                                                  
  Age, median years                                           52                                            1.005 (0.973--1.039)      0.745
  Body mass index, median kg/m^2^                             27.6                                          1.042 (0.974--1.116)      0.229
  Creatinine, median mg/dl                                    1.2                                           1.209 (0.524--2.167)      0.524
  BVAS/WG score, median                                       8                                             1.121 (0.994--1.264)      0.063
  C‐reactive protein, median mg/dl                            3.03                                          1.051 (0.960--1.150)      0.282
  GPA vs. MPA, %                                              74.7                                          1.941 (0.529--7.125)      0.317
  Newly diagnosed disease vs. relapsing disease, %            48.7                                          1.067 (0.400--2.844)      0.896
  PR3 vs. MPO positivity, %                                   66.5                                          7.731 (1.021--58.545)     0.048
  Proteinuria (dipstick), %                                   72.1                                          0.675 (0.358--1.274)      0.226
  Serum albumin, median gm/dl                                 3.75                                          1.353 (0.549--3.333)      0.511
  Male sex, %                                                 50.7                                          1.319 (0.491--3.542)      0.583
  Disease manifestations, %                                                                                                           
  Arthralgia                                                  56.3                                          0.988 (0.368--2.653)      0.981
  Eye involvement                                             23.4                                          0.032 (0.000--4.322)      0.169
  Heart involvement                                           0.5                                           17.408 (2.247--134.842)   0.006
  Peripheral nervous system involvement                       19.3                                          0.966 (0.275--3.391)      0.957
  Pulmonary hemorrhage                                        25.9                                          3.889 (1.448--10.448)     0.008
  Red blood cell casts                                        23.8[†](#art41017-note-0007){ref-type="fn"}   15.617 (3.491--69.854)    \<0.001
  Renal involvement[‡](#art41017-note-0008){ref-type="fn"}    28.5                                          2.238 (0.638--7.855)      0.208
  Sinusitis                                                   54.8                                          0.355 (0.123--1.023)      0.055
  Skin involvement                                            17.3                                          1.634 (0.527--5.070)      0.395
  VDI at baseline, median                                     1.18                                          0.793 (0.528--1.192)      0.265
  Treatment modalities, %                                                                                                             
  Antihypertensive agents                                     100                                           1.189 (0.788--1.794)      0.410
  Diuretic use (single agent)                                 24.9                                          1.389 (0.482--4.000)      0.542
  Methylprednisolone bolus                                    64.5                                          0.415 (0.154--1.114)      0.081
  Rituximab vs. cyclophosphamide                              50.8                                          0.747 (0.278--2.006)      0.563
  Sequential nephron blockade (loop and thiazide diuretics)   2.5                                           1.001 (0.623--1.609)      0.995
  Cumulative steroid dose (6 months), median gm               3.99                                          0.673 (0.426--1.064)      0.090
  Follow‐up variables, %                                                                                                              
  Infection                                                   82.2                                          1.526 (0.347--6.716)      0.526
  Malignancy                                                  3.6                                           0.047 (0.000--4,691.49)   0.603
  Relapse                                                     40.1                                          1.437 (0.539--3.831)      0.511
  VDI change (\>1)[§](#art41017-note-0009){ref-type="fn"}                                                   0.998 (0.817--1.219)      0.984

VTE = venous thromboembolism; HR = hazard ratio; 95% CI = 95% confidence interval; BVAS/WG = Birmingham Vasculitis Activity Score for Wegener\'s Granulomatosis; GPA = granulomatosis with polyangiitis; MPA = microscopic polyangiitis; PR3 = proteinase 3; MPO = myeloperoxidase; VDI = Vasculitis Damage Index.

Data were available for 165 patients.

Renal involvement was defined as the presence of significant hematuria, red blood cell casts, or reduced creatinine clearance (attributable to active vasculitis).

Excluding pulmonary infarction and complicated venous thrombosis.

John Wiley & Sons, Ltd

###### 

Clinical associations with venous thromboembolism events in antineutrophil cytoplasmic antibody--associated vasculitis, determined by multivariate analysis of variables that had significant associations in the univariate analysis[\*](#art41017-note-0010){ref-type="fn"}

  Variable                  Hazard ratio (95% CI)     *P*
  ------------------------- ------------------------- ---------
  Heart involvement         21.836 (2.566--185.805)   0.005
  Pulmonary hemorrhage      3.910 (1.453--10.522)     0.007
  Proteinase 3 positivity   9.120 (1.158--71.839)     0.036
  Red blood cell casts      16.455 (3.607--75.075)    \<0.001

Multivariate Cox regression models were adjusted for age and sex. 95% CI = 95% confidence interval.

John Wiley & Sons, Ltd

Discussion {#art41017-sec-0015}
==========

A hallmark of some systemic autoimmune diseases is their association with thrombosis [13](#art41017-bib-0013){ref-type="ref"}. Consistent with this, several studies have shown that patients with AAV are at increased risk of developing thrombosis [3](#art41017-bib-0003){ref-type="ref"}, [5](#art41017-bib-0005){ref-type="ref"}, [13](#art41017-bib-0013){ref-type="ref"}. When analyzing data from the RAVE trial, we observed VTE events in 8.1% of patients enrolled in the study. A majority of events (12 of 16) was recorded within the first 2 months of enrollment, highlighting the role of inflammation and presumably active disease in the onset of VTE. These findings align with previous results from the WGET trial, which indicated an increased risk of VTE in this patient population and a median time to event onset of 2.1 months [3](#art41017-bib-0003){ref-type="ref"}. Moreover, we identified a trend toward an association between VTE and disease activity. A recent analysis of 417 patients from several randomized trials demonstrated an association between higher disease activity and VTE events [6](#art41017-bib-0006){ref-type="ref"}, reinforcing the role of active vasculitis in predisposing individuals to thrombosis.

Several mechanisms may contribute to the procoagulable state in AAV. Antiplasminogen antibody titers have been shown to be higher in patients with PR3‐positive vasculitis compared to patients with either MPO‐positive vasculitis or idiopathic thrombosis, and these antibodies were detected in 5 of 9 vasculitis patients with thrombosis and PR3‐ANCA positivity compared to none of 4 patients with thrombosis and MPO‐ANCA positivity [7](#art41017-bib-0007){ref-type="ref"}. Antiplasminogen antibodies also reacted with a highly restricted motif on plasminogen [7](#art41017-bib-0007){ref-type="ref"}, indicating their potential to impair fibrinolysis, which may explain our findings demonstrating a higher frequency of VTE in patients positive for PR3‐ANCA. Moreover, patients with GPA exhibit an increased frequency of anticardiolipin antibodies when compared to the general population [14](#art41017-bib-0014){ref-type="ref"}. The association between pulmonary hemorrhage and VTE in patients with AAV has not been previously described. A case series of patients with severe pulmonary hemorrhage due to systemic vasculitis showed a concomitant VTE event in 7 of 35 patients [15](#art41017-bib-0015){ref-type="ref"}. It is tempting to speculate that these patients are prone to develop thrombosis due to more severe disease, as shown in our study. We found an association between the presence of urinary RBC casts and VTE, while renal involvement in general was not associated with VTE. One can speculate that presence of RBC casts is related to active glomerular inflammation and that inflammation in itself is triggering VTE.

Our work has several strengths and limitations. Since the RAVE study was a randomized controlled trial, the quality and completeness of the data (which are publicly accessible) are more appropriate compared to most other studies investigating VTE. Among the study\'s limitations, we only assessed clinically apparent VTE events (i.e., not investigated in a protocolized, prospective manner), and the definition of alveolar hemorrhage was left to site investigators. Due to the low number of events, adjustment for multiple comparisons was restricted to age and sex. Moreover, data on some variables, such as serum albumin and proteinuria (measured by dipstick), were not available for every participant.

In conclusion, our post hoc analysis of a prospective randomized controlled trial of patients with AAV has identified several factors associated with VTE risk. Patients with pulmonary hemorrhage may be prone to VTE. We identified PR3 positivity as a novel risk factor, which might be related to more frequent presence of antiplasminogen antibodies. The association between heart involvement and presence of RBCs has not been previously described and may reflect the contribution of overall disease burden to the risk of thrombotic complications. Further studies are needed to confirm and expand these findings and to explore the mechanisms of hypercoagulability in these patients with the aim of informing potential targets for therapeutic interventions.
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